1981
The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture
Devita V. The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture. Cancer 1981, 47: 1-13. PMID: 6970069, DOI: 10.1002/1097-0142(19810101)47:1<1::aid-cncr2820470102>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseLong-term adverse consequencesPresence of symptomsNational Cancer InstituteMOPP programComplete remissionNodular sclerosisHistologic subtypeImmunosuppressive drugsNational mortalityEffective chemotherapyDrug treatmentCancer InstituteChemotherapyDiseaseCarcinogenic effectsAdverse effectsYoung populationMOPPAdverse consequencesImportant negative influenceRemissionSclerosisPatientsPrognosis
1979
A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma
Brereton H, Young R, Longo D, Kirkland L, Berard C, Jaffe E, Devita V, Johnson R. A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma. Cancer 1979, 43: 2227-2231. PMID: 378350, DOI: 10.1002/1097-0142(197906)43:6<2227::aid-cncr2820430611>3.0.co;2-j.Peer-Reviewed Original Research
1978
Hodgkin's Disease: An Overview
LEWIS B, DeVITA V. Hodgkin's Disease: An Overview. Southern Medical Journal 1978, 71: 1546-1552. PMID: 83007, DOI: 10.1097/00007611-197812000-00029.Peer-Reviewed Original ResearchHexamethylmelamine in alkylating agent‐resistant ovarian carcinoma
Johnson B, Fisher R, Bender R, Devita V, Chabner B, Young R. Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma. Cancer 1978, 42: 2157-2161. PMID: 102417, DOI: 10.1002/1097-0142(197811)42:5<2157::aid-cncr2820420511>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsDose modificationOvarian cancerDiscontinuation of therapyAdvanced ovarian cancerMedian durationObjective responseAgent therapyProspective studyOvarian carcinomaDay courseSevere toxicityPatientsAttractive agentTherapyToxic effectsHexamethylmelamineCancerDegree of toxicityToxicityActive agentsDiscontinuationChemotherapyNeurologicCarcinomaHematologicCombination therapy of the lymphomas.
Lewis B, DeVita V. Combination therapy of the lymphomas. Seminars In Hematology 1978, 15: 431-57. PMID: 366762.Peer-Reviewed Original ResearchThe chemotherapy of Hodgkin's disease. Past experiences and future directions
Devita V, Lewis B, Rozencweig M, Muggia F. The chemotherapy of Hodgkin's disease. Past experiences and future directions. Cancer 1978, 42: 979-990. PMID: 356960, DOI: 10.1002/1097-0142(197808)42:2+<979::aid-cncr2820420721>3.0.co;2-s.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombination chemotherapyAntitumor response rateAdvanced Hodgkin's diseaseComplete remissionDrug therapyDrug combinationsEffective treatmentTherapeutic experimentsAntitumor effectsResponse rateChemotherapyClinical investigatorsNatural historyEffective agentDiseasePatientsMarked increaseTreatmentNitrogen mustardRemissionTherapyDiffuse histiocytic lymphoma involving the gastrointestinal tract
Hande K, Fisher R, Devita V, Chabner B, Young R. Diffuse histiocytic lymphoma involving the gastrointestinal tract. Cancer 1978, 41: 1984-1989. PMID: 348299, DOI: 10.1002/1097-0142(197805)41:5<1984::aid-cncr2820410544>3.0.co;2-8.Peer-Reviewed Original ResearchConceptsDiffuse histiocytic lymphomaBowel perforationComplete remissionSurgical resectionHistiocytic lymphomaGastrointestinal tractActive chemotherapeutic regimensMassive intestinal hemorrhageMajority of patientsResults of stagingRigorous stagingGastrointestinal lymphomaSystemic chemotherapySystemic therapyBowel lesionsChemotherapeutic regimensIntestinal hemorrhageDrug therapyRadiation therapyPatientsTumor resistanceLymphomaTherapyRelative rarityWidespread disease
1977
Peritoneoscopy: a technique to evaluate therapeutic efficacy in non-Hodgkin's lymphoma patients.
Anderson T, Bender R, Rosenoff S, Brereton H, Chabner B, DeVita V, Hubbard S, Young R. Peritoneoscopy: a technique to evaluate therapeutic efficacy in non-Hodgkin's lymphoma patients. Journal Of The National Cancer Institute 1977, 61: 1017-22. PMID: 143345.Peer-Reviewed Original ResearchConceptsHodgkin's lymphoma patientsPercutaneous liver biopsyLymphoma patientsHepatic involvementLiver biopsyComplete clinical remissionLow morbidity rateActive diseaseClinical relapseClinical remissionIntensive chemotherapyPersistent diseaseLess morbidityMorbidity rateHodgkin's lymphomaPatientsTherapeutic efficacyBiopsyRelapseLymphomaDiseaseInvolvementLaparotomyRemissionMorbidityProceedings of the Conference on non-Hodgkin's lymphomas: summary of symposium.
DeVita V. Proceedings of the Conference on non-Hodgkin's lymphomas: summary of symposium. Journal Of The National Cancer Institute 1977, 61: 1223-7. PMID: 332356.Peer-Reviewed Original ResearchAdvanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Young R, Johnson R, Canellos G, Chabner B, Brereton H, Berard C, DeVita V. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Journal Of The National Cancer Institute 1977, 61: 1153-9. PMID: 332349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood PlateletsClinical Trials as TopicCyclophosphamideDrug Therapy, CombinationFemaleHumansLeukocytesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm StagingPrednisoneProcarbazineProspective StudiesRadiation DosageRadiation InjuriesRemission, SpontaneousTime FactorsVincristineConceptsHigher overall response rateCyclic combination chemotherapyOverall response rateCombination chemotherapyMedian followupResponse rateSimilar complete remission ratesRelapse-free survival rateComparison of chemotherapyMonths median followupComplete remission rateOverall median survivalDisease-free survivalTotal body irradiationNodular mixed lymphomaInduction regimenInduction therapyComplete remissionMedian survivalProspective trialRemission rateUntreated patientsMixed lymphomaMalignant lymphomaNodular lymphomaCombination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.
Anderson T, Bender R, Fisher R, DeVita V, Chabner B, Berard C, Norton L, Young R. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Journal Of The National Cancer Institute 1977, 61: 1057-66. PMID: 71205.Peer-Reviewed Original ResearchAdolescentAdultAgedBleomycinChildClinical Trials as TopicCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHumansLymphomaLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission, SpontaneousTime FactorsVincristinePrognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy
Fisher R, DeVita V, Johnson B, Simon R, Young R. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. The American Journal Of Medicine 1977, 63: 177-182. PMID: 70170, DOI: 10.1016/0002-9343(77)90230-3.Peer-Reviewed Original ResearchCharacteristics of blast crisis in chronic granulocytic leukemia.
Rosenthal S, Canellos G, DeVita V, Gralnick H. Characteristics of blast crisis in chronic granulocytic leukemia. Blood 1977, 49: 705-14. PMID: 265737, DOI: 10.1182/blood.v49.5.705.bloodjournal495705.Peer-Reviewed Original ResearchConceptsChronic granulocytic leukemiaBlast crisisExtramedullary leukemiaGranulocytic leukemiaDiagnosis of blast crisisPh1-positive chronic granulocytic leukemiaLymphoblastic groupAcute leukemiaPeripheral bloodHematological criteriaHematological featuresBone marrowLeukemiaMorphological subgroupsPatientsThrombocytopeniaTerminal phaseMarrow
1976
Combined modality treatment of American Burkittapos;s lymphoma
Ziegler J, Devita V, Graw R, Herzig G, Leventhal B, Levine A, Pomeroy T. Combined modality treatment of American Burkittapos;s lymphoma. Cancer 1976, 38: 2225-2231. PMID: 1036716, DOI: 10.1002/1097-0142(197612)38:6<2225::aid-cncr2820380606>3.0.co;2-f.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaCombined modality treatmentBone marrow autograftsMajor therapeutic goalPrevention of relapseThird remissionFirst remissionIntensive chemotherapyComplete responseModality treatmentInitial treatmentAmerican patientsMarrow autograftsRisk factorsClinical trialsTherapeutic goalsPatientsLymphomaRemissionChemotherapyTreatmentImmunotherapyRelapseRadiotherapyAutograftBleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Schein P, DeVita V, Hubbard S, Chabner B, Canellos G, Berard C, Young R. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Annals Of Internal Medicine 1976, 85: 417-22. PMID: 61732, DOI: 10.7326/0003-4819-85-4-417.Peer-Reviewed Original ResearchConceptsHistiocytic lymphomaAdvanced diffuse histiocytic lymphomaExtended disease-free survivalMixed histiocytic-lymphocytic lymphomaNew combination chemotherapy programHistiocytic-lymphocytic lymphomaPrednisone combination chemotherapyCompletion of therapyDiscontinuation of treatmentCombination chemotherapy programsDisease-free survivalDiffuse histiocytic lymphomaBone marrow functionMyelosuppressive phaseComplete remissionMedian durationChemotherapy programCombination chemotherapyComplete responseMarrow functionTumor recurrenceTreatment cyclesFatal diseasePatientsLymphomaChemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy.
Canellos G, DeVita V, Whang-Peng J, Chabner B, Schein P, Young R. Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy. Blood 1976, 47: 1003-9. PMID: 1064434, DOI: 10.1182/blood.v47.6.1003.bloodjournal4761003.Peer-Reviewed Original ResearchConceptsChromosome-positive chronic granulocytic leukemiaChronic granulocytic leukemiaBlastic phaseComplete remissionPrior splenectomyComplete remittersGranulocytic leukemiaCytosine arabinosidePhiladelphia chromosome-positive chronic granulocytic leukemiaNonsplenectomized groupPrednisone groupPartial remissionMedian survivalElective splenectomyPartial responseSecondary therapyChronic phaseOpposite regimenRemissionSplenectomyVincristinePrednisoneChemotherapyPatientsCell lines
1975
In vitro granulocyte production in patients with Hodgkin's disease and lymphocytic, histiocytic, and mixed lymphomas.
Bull J, DeVita V, Carbone P. In vitro granulocyte production in patients with Hodgkin's disease and lymphocytic, histiocytic, and mixed lymphomas. Blood 1975, 45: 833-42. PMID: 1125431, DOI: 10.1182/blood.v45.6.833.bloodjournal456833.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseMixed lymphomaUntreated patientsHistiocytic-lymphocytic lymphomasAdvanced Hodgkin's diseaseMOPP chemotherapyGranulocyte colony formationCombination chemotherapyMarrow culturesCFU-CIn vitro examinationLymphomaChemotherapyGranulocyte productionPatientsLong-term effectsAcute responseHodgkinColony formationDecreased numberDiseaseColony growthSECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION
Canellos G, Arseneau J, Devita V, Whang-Peng J, Johnson R. SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION. The Lancet 1975, 305: 947-949. PMID: 48122, DOI: 10.1016/s0140-6736(75)92007-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsCarcinoma, Squamous CellChromosome AberrationsColonic NeoplasmsFemaleFibrosarcomaHodgkin DiseaseHumansImmunosuppression TherapyLeukemia, Monocytic, AcuteLeukemia, Myeloid, AcuteLung NeoplasmsMaleMiddle AgedNeoplasmsNeoplasms, Radiation-InducedRadiotherapyRemission, SpontaneousSkin NeoplasmsConceptsIntensive radiotherapyCombination chemotherapyPatients treated with standard chemotherapyCourse of Hodgkin's diseaseRelapse of diseaseAcute myeloid leukemiaMan-years of follow-upMode of treatmentMechanisms of oncogenesisStandard chemotherapyHodgkin's diseaseChromosomal abnormalitiesMyeloid leukemiaImmunosuppressive effectsRadiotherapyFollow-upChemotherapyTumorHigh riskCellular effectsPatientsDiseaseIncidenceTreatmentRiskTherapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy.
Canellos G, DeVita V, Young R, Chabner B, Schein P, Johnson R. Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy. British Journal Of Cancer. Supplement 1975, 2: 474-80. PMID: 1101933, PMCID: PMC2149565.Peer-Reviewed Original ResearchResults of combination chemotherapy of non-Hodgkin's lymphoma.
Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Results of combination chemotherapy of non-Hodgkin's lymphoma. British Journal Of Cancer. Supplement 1975, 2: 465-73. PMID: 1101932, PMCID: PMC2149606.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's lymphomaCombination chemotherapyHistological subgroupsLymphocytic lymphomaMonths of treatmentDiffuse histiocytic lymphomaMOPP chemotherapyMedian durationLate recurrenceLymph nodesNodular histologyHistiocytic lymphomaRemissionExtended survivalBone marrowClinical validityLymphomaAdvanced stageChemotherapyPatientsRelapseInitial siteMonthsSurvival